Pyridine polycyclic compound inhibitor, preparation method therefor and use thereof
AssigneesShanghai Hansoh Biomedical Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
InventorsYidong SU, Xiaofeng MAO, Wensheng YU, Jun WANG, Kailong LI
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pyridine polycyclic compound inhibitor, a preparation method therefor and a use thereof. In particular, the present invention relates to a compound represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising the compound, and a use of the compound in a medication for treating chronic kidney disease, kidney or cardiac fibrosis, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism, and Cushing syndrome, wherein the definitions of the substituents in formula (I) are the same as those in the description.
Claims22
A compound represented by general formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof:
- wherein:
- is a single bond or a double bond;
- ring A is 5- to 7-membered heterocyclyl containing 2-3 heteroatoms selected from N, O, or S, and ring A contains at least one oxygen atom;
- ring B is 5- to 6-membered heteroaryl or phenyl;
- ring C is cycloalkyl, heteroaryl, heterocyclyl, or absent;
- M1, M2, M4, M5, and M6 are each independently selected from N, C, NH, or CH;
- M3 is a bond, N, or CH;
- each R1 is independently selected from cycloalkyl, heterocyclyl, cycloalkyloxy, heterocyclyloxy, cycloalkylamino, heterocyclylamino, cycloalkylthio, heterocyclylthio, —C(O)(CH2)nRb, —NRaC(O)(CH2)nRb, —O(CH2)nRb, —NH(CH2)nRb, —S(CH2)nRb, —S(O)2(CH2)nRb, —S(O)(NH)(CH2)nRb, —NRaS(O)2(CH2)nRb, —NRaS(O)(NH)(CH2)nRb, or —NS(O)(CH2)nRaRb, wherein optionally the cycloalkyl, heterocyclyl, cycloalkyloxy, heterocyclyloxy, cycloalkylamino, heterocyclylamino, cycloalkylthio, or heterocyclylthio is further substituted with one or more substituents selected from oxo, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, deuteroalkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, —C(O)(CH2)nRb, —S(O)2(CH2)nRb, —S(O)(NH)(CH2)nRb, —S(O)2(CH2)nRb, or —NRaS(O)(NH)(CH2)nRb;
- or any two R1, together with adjacent carbon atoms, form 3- to 8-membered cycloalkyl or 4- to 7-membered heterocyclyl, wherein optionally the 3- to 8-membered cycloalkyl or 4- to 7-membered heterocyclyl is further substituted with oxo, —C(O)Rb, —NRaC(O)Rb, —S(O)2Rb, —S(O)(NH)Rb, —NRaS(O)2Rb, or —NRaS(O)(NH)Rb;
- Ra or Rb is each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, deuteroalkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, wherein optionally the cycloalkyl, aryl, heteroaryl, or heterocyclyl is further substituted with one or more substituents selected from oxo, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, deuteroalkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, or —S(O)2alkyl;
- R2, R3, or R4 is each independently selected from hydrogen, deuterium, oxo, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, deuteroalkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, deuteroalkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —NRaC(O)(CH2)nRb, or —C(O)NRa(CH2)nRb can be optionally further substituted;
- or R2 and R3, together with adjacent atoms, form 3- to 8-membered cycloalkyl, 5- to 6-membered heteroaryl, or 4- to 7-membered heterocyclyl, wherein optionally the 3- to 8-membered cycloalkyl, 5- to 6-membered heteroaryl, or 4- to 7-membered heterocyclyl is further substituted with one or more substituents selected from oxo, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, deuteroalkyl, haloalkyl, alkoxy, haloalkoxy, or hydroxyalkyl;
- or any two R2, together with adjacent atoms, form 3- to 8-membered cycloalkyl, 5- to 6-membered heteroaryl, or 4- to 7-membered heterocyclyl, wherein optionally the 3- to 8-membered cycloalkyl, 5- to 6-membered heteroaryl, or 4- to 7-membered heterocyclyl is further substituted with one or more substituents selected from oxo, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, deuteroalkyl, haloalkyl, alkoxy, haloalkoxy, or hydroxyalkyl;
- or R2 and R4, together with adjacent atoms, form 5- to 14-membered cycloalkyl, 5- to 14-membered heteroaryl, or 5-14-membered heterocyclyl, wherein optionally the 5- to 14-membered cycloalkyl, 5- to 14-membered heteroaryl, or 5-14-membered heterocyclyl is further substituted with one or more substituents selected from oxo, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, deuteroalkyl, haloalkyl, alkoxy, haloalkoxy, or hydroxyalkyl;
- p, x, y, and z are each independently selected from 1, 2, 3, or 4;
- and
- n is selected from 0, 1, 2, or 3.
A compound as follows, or a stereoisomer or a pharmaceutically acceptable salt thereof:
(canceled)
(canceled)
Dependencies are inferred from the claim text.